Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an announcement.
Australian Clinical Labs Limited announced the cessation of 38,121 service rights due to unmet conditions, impacting its issued capital. This development may influence the company’s financial structure and could have implications for stakeholders regarding the company’s operational and strategic adjustments.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, focusing on providing pathology services across Australia. The company is known for its comprehensive range of diagnostic testing services, catering to both the public and private healthcare sectors.
Average Trading Volume: 785,388
Technical Sentiment Signal: Buy
Current Market Cap: A$546.7M
See more data about ACL stock on TipRanks’ Stock Analysis page.